Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3482.3482
Abstract: Background : ALXN1210 is a rationally designed humanized monoclonal antibody to complement component 5 (C5), engineered to achieve extended half-life and duration of complement inhibition while retaining the proven efficacy and safety of eculizumab. Objective… read more here.
Keywords: pharmaceuticals inc; alexion pharmaceuticals; induction; complement inhibitor ... See more keywords